+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treatment With Quadrivalent Human Papillomavirus Vaccine for Juvenile-Onset Recurrent Respiratory Papillomatosis: Case Report and Review of the Literature



Treatment With Quadrivalent Human Papillomavirus Vaccine for Juvenile-Onset Recurrent Respiratory Papillomatosis: Case Report and Review of the Literature



Journal of the Pediatric Infectious Diseases Society 6(4): 380-385



Although juvenile-onset recurrent respiratory papillomatosis (JoRRP) generally involves a benign tumor on the larynx and other respiratory tract areas, almost all patients with this disease require repeated surgical intervention (to prevent airway obstruction during the course of illness) and various adjuvant therapies such as interferon, cidofovir, acyclovir, ribavirin, indole-3-carbinol, HspE7, mumps vaccine, photodynamic therapy, propranolol, cimetidine, and bevacizumab. Some case reports recently described the effectiveness of the quadrivalent human papillomavirus vaccine (HPV4) as an adjuvant therapy. On the basis of these reports, we administered HPV4 to a 2-year-old boy with JoRRP. However, no therapeutic effect was found. A review of the available literature revealed that current evidence for the effectiveness of therapeutic HPV4 and other adjuvant therapies for JoRRP is inconsistent. Therefore, the prophylactic use of currently available HPV vaccine for adolescents is the most effective strategy for preventing not only anogenital cancers but also genital warts, which might be a risk factor for JoRRP among their children in the future.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 060424924

Download citation: RISBibTeXText

PMID: 28992265

DOI: 10.1093/jpids/pix063


Related references

Juvenile-Onset Recurrent Respiratory Papillomatosis: The Benefits of Quadrivalent Human Papillomavirus Vaccination Continue to Accrue. Journal of Infectious Diseases 217(2): 177-178, 2018

Intersurgical interval increased with use of quadrivalent human papillomavirus vaccine (Gardasil) in a pediatric patient with recurrent respiratory papillomatosis: A case report. International Journal of Pediatric Otorhinolaryngology 91: 166-169, 2016

Juvenile-onset recurrent respiratory papillomatosis involving the lung: A case report and review of the literature. Pediatric and Developmental Pathology 1(2): 157-163, 1998

Time course of juvenile onset recurrent respiratory papillomatosis caused by human papillomavirus. Pediatric Infectious Disease Journal 27(2): 149-154, 2008

Antibody response to human papillomavirus (HPV) type 11 in children with juvenile-onset recurrent respiratory papillomatosis (RRP). Virology 188(1): 384-387, 1992

Human papillomavirus and host variables as predictors of clinical course in patients with juvenile-onset recurrent respiratory papillomatosis. Journal of Clinical Microbiology 35(12): 3098-3103, 1997

Lung involvement in juvenile onset recurrent respiratory papillomatosis: a systematic review of the literature. International Journal of Pediatric Otorhinolaryngology 72(4): 433-452, 2008

Nucleotide and phylogenetic analysis of human papillomavirus type 11 isolated from juvenile-onset recurrent respiratory papillomatosis in China. Journal of Medical Virology 88(4): 686-694, 2016

Recurrent laryngeal papillomatosis with oesophageal involvement in a 2 year old boy: successful treatment with the quadrivalent human papillomatosis vaccine. International Journal of Pediatric Otorhinolaryngology 79(2): 262-266, 2015

A case for immunization of human papillomavirus (HPV) 6/11-infected pregnant women with the quadrivalent HPV vaccine to prevent juvenile-onset laryngeal papilloma. Journal of Infectious Diseases 209(9): 1307-1309, 2014

The use of the quadrivalent human papillomavirus vaccine (gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma. Journal of Voice 29(2): 223-229, 2015

Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis. European Archives of Oto-Rhino-Laryngology 273(10): 3231-3236, 2016

The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine 26(35): 4513-4518, 2008

Effectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory papillomatosis. International Journal of Pediatric Otorhinolaryngology 83: 94-98, 2016

Experimental research on the therapeutic effect of MMR vaccine to juvenile-onset recurrent respiratory papillomatosis. European Archives of Oto-Rhino-Laryngology 276(3): 801-803, 2019